Dr. Yanliang Zhang's lab at the University of Notre Dame focuses on advancing 3D bioprinting technology to create complex, functional blood vessel structures. By integrating various printing methods, their goal is to develop improved vascular tissues that can perform essential biological functions and facilitate tissue repair. This cutting-edge research has the potential to significantly impact regenerative medicine and organ engineering.

Dr. Kristin Valentino's lab focuses on innovative approaches to reduce suicidal behaviors, especially among adolescents. The lab explores the use of noninvasive technologies, like transcutaneous vagus nerve stimulation (tVNS) and smartphone apps, to provide effective mental health support. Through their research, they aim to target emotional dysregulation and social isolation - two key factors that contribute to suicide risk in young people.

Dr. Elizabeth Archie’s lab focuses on understanding how social and environmental stressors throughout life affect health, particularly as we age. By using nonhuman primates, specifically baboons, the lab develops innovative tools to measure stress responses and their impacts on heart health. The findings have implications for better understanding health outcomes related to stress and aging in humans.

Dr. Brian S. J. Blagg's lab at the University of Notre Dame is engaged in innovative cancer research focused on developing targeted therapies. The lab primarily investigates inhibitors of heat shock proteins and their potential to treat challenging cancers, particularly prostate cancer and glaucoma. By creating specific inhibitors that reduce side effects and enhance the effectiveness of existing treatments, the lab aims to improve outcomes for patients with these serious conditions.

Edward Mark Cummings' lab focuses on developing and evaluating evidence-based family support programs, particularly for families affected by conflict and political violence. The lab's main project, Promoting Positive Family Futures (PPFF), aims to improve the well-being of children and parents in regions facing chronic adversity, such as Palestine. By employing a randomized clinical trial design, the lab seeks to test the efficacy of their interventions and their impacts on family dynamics and adolescent emotional health.

Dr. David R. Hyde's lab at the University of Notre Dame focuses on understanding why zebrafish can regenerate retinal neurons after acute damage, but not after chronic damage. This research is crucial for developing therapies to treat human vision loss caused by gradual retinal degeneration. Through innovative techniques, the lab explores the roles of retinal cells and immune responses in the regeneration process, aiming to leverage these insights for clinical applications.

Dr. Michael Ferdig's lab focuses on understanding drug resistance in malaria, particularly how the malaria parasite, Plasmodium falciparum, adapts to treatments like artemisinin and its partner drug lumefantrine. Through experimental genetic crosses and advanced genetic techniques, the team seeks to pinpoint the specific genes that contribute to resistance. This research is crucial for public health, as rising drug resistance threatens malaria control efforts in Africa, where the disease remains a major health crisis.

Dr. Laura E. Miller-Graff leads a research lab focused on improving mental health and child welfare through innovative intervention programs. Her lab conducts studies in high-need areas, particularly examining how maternal mental health can affect child maltreatment and intergenerational outcomes. The aim is to develop evidence-based approaches that can be adapted for use in low-resource settings like Peru, ultimately impacting both local and global public health.

Dr. Shahriar Mobashery's lab at the University of Notre Dame focuses on understanding how the bacterium Staphylococcus aureus becomes resistant to beta-lactam antibiotics, which are crucial for treating infections. The research aims to identify novel agents that could reverse this resistance and restore the efficacy of these antibiotics. The lab employs various techniques to study the genetic and molecular mechanisms involved in this antibiotic resistance.

Dr. Patricia A Champion's lab at the University of Notre Dame focuses on understanding how pathogenic mycobacteria, like Mycobacterium tuberculosis, cause diseases in humans. They specifically study the ways in which these bacteria adapt to different pH levels in the body and how that impacts their ability to survive and infect. Through innovative research techniques, the lab aims to uncover new insights into treatment and prevention strategies for mycobacterial infections.

Dr. Brian M Baker's lab at the University of Notre Dame focuses on understanding how mechanical forces influence T cell behavior in the immune system. The research involves studying the interactions between T cell receptors and peptide-MHC complexes, particularly how these interactions can change under different forces. By developing models to explain these interactions, the lab aims to manipulate T cell responses, which could lead to better strategies in immunotherapy and vaccine design.

Dr. Juan R Del Valle's research lab focuses on understanding tau protein, which is associated with neurodegenerative diseases affecting memory and cognitive function. The lab develops synthetic peptides that mimic the structure of misfolded tau to investigate how these proteins propagate in the brain and contribute to disease progression. Their innovative approach aims to generate tools that can help in the early diagnosis and treatment of these conditions.

Dr. Matthew Webber's lab at the University of Notre Dame focuses on developing innovative insulin therapies for diabetes management. They aim to create a once-weekly insulin formulation that responds to blood glucose levels, making it easier for patients to control their diabetes. By combining advanced materials and chemical modifications, the lab seeks to improve patient adherence and enhance therapeutic outcomes while minimizing risks associated with insulin therapy.